Evidence map›Paper›PMID 29751029›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2018

Accelerated wound healing by injectable star poly(ethylene glycol)-b-poly(propylene sulfide) scaffolds loaded with poorly water-soluble drugs.

Suwei Zhu, Shuoran Li, Helena Escuin-Ordinas, Robert Dimatteo, Weixian Xi, Antoni Ribas, Tatiana Segura

2 registry-linked trialsOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07463365 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Phase 1, Open-Label Clinical Trial to Assess the Safety, Tolerability, and Preliminary Efficacy Study of Topically Administered LUT017 Gel for Cutaneous Wound Healing

TypeinterventionalSponsorAntoni RibasRan2026 to 2027Enrolled18ConditionsVenous Leg Ulcer, Chronic Non-Healing Cutaneous Wounds, VLUArmsLUT017 gel
NCT07463378 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Phase 1, Open-Label Clinical Trial to Assess the Safety, Tolerability, and Preliminary Efficacy Study of a Single Dose of Topically Administered LUT017 Gel for Cutaneous Wound Healing in Volunteers With Healthy Skin

TypeinterventionalSponsorAntoni RibasRan2026 to 2027Enrolled9ConditionsWound Healing, Acute Skin WoundsArmsLUT017,Topical BRAF inhibitor
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Recent Advances inGels (Basel, Switzerland) · 2023
    Review
  6. Review
  7. Article
  8. Article
  9. Citrullination of fibronectin alters integrin clustering and focal adhesion stability promoting stromal cell invasion.Matrix biology : journal of the International Society for Matrix Biology · 2019
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Suwei ZhuDepartment of Chemical and Biomolecular Engineering, University of California, Los Angeles, 420 Westwood Plaza, 5531 Boelter Hall, Los Angeles, CA 90095, United States.
Shuoran LiDepartment of Chemical and Biomolecular Engineering, University of California, Los Angeles, 420 Westwood Plaza, 5531 Boelter Hall, Los Angeles, CA 90095, United States.
Helena Escuin-OrdinasDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, 420 Westwood Plaza, 5531 Boelter Hall, Los Angeles, CA 90095, United States.
Robert DimatteoDepartment of Chemical and Biomolecular Engineering, University of California, Los Angeles, 420 Westwood Plaza, 5531 Boelter Hall, Los Angeles, CA 90095, United States.
Weixian XiDepartment of Chemical and Biomolecular Engineering, University of California, Los Angeles, 420 Westwood Plaza, 5531 Boelter Hall, Los Angeles, CA 90095, United States; Department of Orthopedic Surgery, University of California, Los Angeles, 420 Westwood Plaza, 5531 Boelter Hall, Los Angeles, CA 90095, United States.
Antoni RibasDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, 420 Westwood Plaza, 5531 Boelter Hall, Los Angeles, CA 90095, United States; Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, 420 Westwood Plaza, 5531 Boelter Hall, Los Angeles, CA 90095, United States; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, 420 Westwood Plaza, 5531 Boelter Hall, Los Angeles, CA 90095, United States; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, 420 Westwood Plaza, 5531 Boelter Hall, Los Angeles, CA 90095, United States.
Tatiana SeguraDepartment of Chemical and Biomolecular Engineering, University of California, Los Angeles, 420 Westwood Plaza, 5531 Boelter Hall, Los Angeles, CA 90095, United States; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, 420 Westwood Plaza, 5531 Boelter Hall, Los Angeles, CA 90095, United States; Department of Biomedical Engineering, Duke Univeristy, 101 Science Drive, PO Box 90281, 27708, United States. Electronic address: tatiana.segura@duke.edu.
University of California, Los Angeles · US

Funding

Next Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4M
Regenerative Musculoskeletal Medicine Training ProgramT32AR059033 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI John S Adams, Nicholas M. Bernthal · 2011 to 2026
$4.8M
VEGF Ligand Presentation and Therapeutic AngiogenesisR01NS079691 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SEGURA, TATIANA · 2012 to 2024
$4.0M
Biotechnology Training in Biomedical Sciences and EngineeringT32GM067555 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GU, ZHEN · 2005 to 2019
$2.8M
Hydrogels for Local Gene Delivery and Therapeutic AngiogenesisR01HL110592 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SEGURA, TATIANA · 2011 to 2015
$1.8M
NCI NIH HHS R35 CA197633NHLBI NIH HHS R01 HL110592NIAMS NIH HHS T32 AR059033NIGMS NIH HHS T32 GM067555NINDS NIH HHS R01 NS079691
6 · The paper itself

Abstract

Injectable hydrogel matrices take the shape of a wound cavity and serve as scaffold for tissue repair and regeneration. Yet these materials are generally hydrophilic, limiting the incorporation of poorly water soluble, hydrophobic drugs. Here we show this shortcoming is circumvented through a star-shaped amphiphilic block copolymer comprising poly(ethylene glycol) and poly (propylene sulfide). This star-shaped amphiphilic polymer self-assembles in an aqueous medium into a physically stable hydrogel and effectively dissolves hydrophobic molecules delivering them at therapeutic doses. The self assembled hydrogel is a robust three-dimensional scaffold in vivo effectively promoting cellular infiltration, reducing inflammation, and wound clsoure. When combined with a hydrophobic BRAF inhibitor that promotes paradoxical mitogen-activated protein kinase (MAPK) activation in keratinocytes and wound closure, our self assembled scaffold supported dermal wound closure at a reduced drug dosage compared to administering the drug in dimethyl sulfoxide (DMSO) without a polymeric matrix. This family of star-shaped amphiphilic polymers delivers poorly water soluble active agents at a fraction of generally required dosage for efficacy and supports three-dimensional cell growth at tissue wounds, showing great promise for novel uses of hydrophobic drugs in tissue repair applications.

Indexed as

AnimalsDrug CarriersHydrogelsHydrophobic and Hydrophilic InteractionsInjectionsMicePolyethylene GlycolsPolymersProtein Kinase InhibitorsSolubilitySulfidesVemurafenibWaterWound HealingDrug CarriersHydrogelsPolyethylene GlycolsPolymerspoly(propylene sulfide)Protein Kinase InhibitorsSulfidesVemurafenibWaterDelivery scaffoldHydrophobic drugsTissue repair

Identifiers

PMID29751029
PMCPMC6082662
OpenAlexW2800191034

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.